Artificial Intelligence
Anavex Life Sciences Reports ANAVEX®2-73 (blarcamesine) featured as a Disease-Modifying Small Molecule in Phase 3 Clinical Trials in a New Publication in Medical Journal titled “Future Avenues for Alzheimer’s Disease Detection and Therapy”
NEW YORK, March 16, 2021 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today reported that ANAVEX®2-73 (blarcamesine) is featured in a recent peer-reviewed publication in the journal of Neuropharmacology, titled “Future avenues for Alzheimer’s disease detection and therapy: liquid biopsy, intracellular signaling modulation, systems pharmacology drug discovery” from the series of the special issue on ’The Quest for Disease-Modifying Therapies for Neurodegenerative Disorders’.1
The authors of the paper describe gene biomarkers associated improved drug response with consistent results across the different measurements of both cognition and activities of daily living and function with ANAVEX®2-73, a selective SIGMAR1 agonist, observed in a 57-week multicenter Phase 2a open-label adaptive design clinical trial (ANAVEX2-73-002) of 32 mild-to-moderate Alzheimer’s disease patients (aged 55–85). They declare that Alzheimer’s disease patients with fully operational SIGMAR1 gene show improved benefits with ANAVEX®2-73, whereas those carrying gene variants have a limited benefit. Since the majority of the population, around 80%, has a totally functional SIGMAR1 gene, most of patients are supposed to benefit from ANAVEX®2-73.
They further state that SIGMAR1 stimulation prevents Aβ-induced neurotoxicity and moreover, that SIGMAR1 activation is associated with a significant slow-down of Alzheimer’s disease-related excitotoxicity, thus promoting synaptic remodeling with improved plasticity. In addition, the biomarker-driven clinical data is described, thus, enabling targeted therapy and a precision medicine-guided approach. PET scan data previously confirmed dose-dependent target engagement of SIGMAR1 with ANAVEX®2-73.2
The precision medicine knowledge from this study was incorporated into the design of the currently ongoing and presently over 86%-enrolled placebo-controlled 450-patient Phase 2b/3 ANAVEX®2-73 clinical study in Alzheimer’s disease including the above characterized SIGMAR1 gene as prespecified endpoints and utilizing differentiated patient selection criteria using ADAS-Cog (cognition) and ADCS-ADL (activities of daily living and function) as primary endpoints.3
The Neuropharmacology publication noted that in the clinical study, 57 weeks of oral once daily ANAVEX®2-73 treatment showed patients improved cognition scores by +2.0 points on MMSE, a 9% mean improvement from baseline to 57 weeks, corresponding to a calculated ADAS-Cog score change of -3.4 (improvement). In these same patients ANAVEX®2-73 also improved ADCS-ADL, by +4.9 points, a 7% mean improvement from baseline to 57 weeks.
An extension of the published study (ANAVEX2-73-003) demonstrated that for the same patients at week 70 MMSE scores improved by +3.0, a 14% improvement from baseline, corresponding to a calculated ADAS-Cog score change of -5.1 (improvement). In these same patients, ANAVEX®2-73 also improved ADCS-ADL, by +6.0 points, an 8% mean improvement from baseline to 70 weeks. The mean MMSE and ADCS-ADL baseline scores for these patients in this study were 22.3 and 71.1, respectively.4,5
This data seems to be consistent with the effect of ANAVEX®2-73 on cognition assessed in the recently completed placebo-controlled Phase 2 study of 132 patients with Parkinson’s disease dementia (ANAVEX2-73-PDD-001) with once-daily administration of oral 30 mg ANAVEX®2-73, 50 mg ANAVEX®2-73 and placebo for 14 weeks. The observed statistically significant improvement of CDR system Episodic Memory of +42.22 between 50 mg ANAVEX®2-73 and placebo was also dose-dependent (p = 0.003).6 CDR system Episodic Memory has been shown to be highly correlated (70%) with the ADAS-Cog score (r = 0.7).7 The calculated corresponding ADAS-Cog mean change from baseline score is -1.9 (improvement) for patients in the 50 mg dose group, an 8% mean improvement from baseline to 14 weeks. The difference between the ANAVEX®2-73 group and the placebo group in the change from baseline at 14 weeks was a 4.0-point improvement of calculated corresponding ADAS-Cog score (p = 0.015).
The Mini-Mental State Exam (MMSE) and the ADAS-Cog (Alzheimer’s Disease Assessment Scale–Cognitive Subscale) are standard tests for assessing changes in cognition in Alzheimer’s disease trials and known to correlate to a high degree.8 The ADCS-ADL (Alzheimer’s Disease Cooperative Study–Activities of Daily Living), assesses the competence of patients with Alzheimer’s disease in basic and instrumental function or activities of daily living.
Alzheimer’s is a progressive disease and over time, a patient’s cognition will always worsen. “Experience based on longitudinal studies of ambulatory patients with mild to moderate Alzheimer’s disease suggest that scores on the ADAS-cog worsen by 6-12 points per year” with the annualized rate of decline might be smaller depending on the disease stage, according to FDA’s Prescription Information sheet for ARICEPT® (donepezil), a drug approved for the treatment of dementia of the Alzheimer’s type.9
While the placebo-controlled 450-patient Phase 2b/3 ANAVEX®2-73 clinical study in Alzheimer’s disease is currently ongoing, prior clinical research in Alzheimer’s disease conducted by other sponsors can serve as a contextual reference for estimates of an expected rate of decline in cognition (MMSE and ADAS-Cog) and function (ADCS-ADL) in placebo patients:
- In 2019, a randomized controlled trial of aducanumab (Biogen) was conducted in >1,000 patients with early Alzheimer’s disease.10 In this Phase 3 study (EMERGE), patients on placebo showed from baseline to week 50 a mean decline in cognition of approximately -2.2 points on MMSE, an 8.3% decline, and from baseline to week 78 approximately -3.3 points on MMSE, a 12.5% decline, respectively. Mean baseline MMSE score was 26.4.
- Large placebo arm data from 20 randomized controlled clinical trials including over 4500 mild-to-moderate Alzheimer’s disease patients treated with standard of care, containing ARICEPT® (donepezil, Eisai) and memantine was analyzed.11 In this analysis, patients on placebo showed from baseline to week 52 a mean decline in cognition of approximately -2.05 points on MMSE, a 10% decline and from baseline to week 78 approximately -3.4 points on MMSE, a 16% decline, respectively, with a calculated mean baseline MMSE score of 21.0. The respective ADAS-Cog decline was 3.9 points from baseline to week 52 and a decline of 6.6 points from baseline to week 78, respectively.
- A randomized controlled study including of ARICEPT® (donepezil, Eisai) and memantine was conducted in >500 patients in the placebo arm with mild-to-moderate Alzheimer’s disease.12 In this Phase 3 study, patients on placebo showed from baseline to week 76 an estimated mean decline in cognition of approximately -3.4 points on MMSE, a 16% decline from baseline. Mean baseline MMSE score was 20.9. The mean ADAS-Cog decline was 6.4 points from baseline to week 76. The mean ADCS-ADL decline was -9.0 points from baseline to week 76.
ANAVEX®2-73 is currently in a late-stage Phase 2b/3 Alzheimer’s disease clinical trial utilizing same dosing regimen as in the above-described completed Parkinson’s disease dementia (ANAVEX2-73-PDD-001) study with differentiated patient selection criteria.13
“This paper highlights the relevance of the analyses of gene expression data in precision medicine to drug development that may predict increased chances of success of Alzheimer’s disease treatments, which is especially relevant in late-stage clinical studies like the ongoing ANAVEX®2-73 Phase 2b/3 clinical Alzheimer’s disease study,” said Christopher U Missling, PhD, President and Chief Executive Officer of Anavex.
ANAVEX®2-73 activates the sigma-1 receptor (SIGMAR1). Data suggests that activation of SIGMAR1 results in the restoration of complete housekeeping function within the body and is pivotal to restoring neural cell homeostasis and promoting neuroplasticity.14
Anavex Life Sciences’ product portfolio includes small molecule drug lead candidate ANAVEX®2-73 for the treatment of Alzheimer’s disease, Parkinson’s disease and Rett syndrome.
About Alzheimer’s Disease
Alzheimer’s disease is a progressive degenerative brain disorder that gradually destroys a person’s memory and ability to learn, reason, make judgments, communicate and carry out daily activities. An estimated 5.7 million Americans have currently Alzheimer’s dementia. Alzheimer’s is the most common cause of dementia among older adults and is estimated to rank as the third leading cause of death for older people in the United States, just behind heart disease and cancer. In 2020, Alzheimer’s and other dementias cost the nation $305 billion. By 2050, these costs could rise as high as $1.1 trillion.15 There are currently over 50 million people living with dementia around the world, with numbers expected to increase to nearly 152 million by 2050.16 Almost 10 million new cases of dementia are diagnosed each year worldwide, implying one new case every 3 seconds, and a significant increase in the caregiving burden placed on society and families.17
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, pain and various types of cancer. Anavex’s lead drug candidate, ANAVEX®2-73 (blarcamesine), recently completed successfully a Phase 2a clinical trials for Alzheimer’s disease and a Phase 2 proof-of-concept study in Parkinson’s disease dementia and a Phase 2 study in adult patients with Rett syndrome. ANAVEX®2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. ANAVEX®2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson’s Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX®2-73 for the treatment of Parkinson’s disease. ANAVEX®3-71, which targets sigma-1 and muscarinic receptors, is a promising clinical stage drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer’s disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies. In preclinical trials, ANAVEX®3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation. Further information is available at www.anavex.com. You can also connect with the company on Twitter, Facebook and LinkedIn.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
For Further Information:
Anavex Life Sciences Corp.
Research & Business Development
Toll-free: 1-844-689-3939
Email: [email protected]
Investors:
Andrew J. Barwicki
Investor Relations
Tel: 516-662-9461
Email: [email protected]
1 Hampel H, Vergallo A, Caraci F, Cuello AC, Lemercier P, Vellas B, Giudici KV, Baldacci F, Hänisch B, Haberkamp M, Broich K, Nisticò R, Emanuele E, Llavero F, Zugaza JL, Lucía A, Giacobini E, Lista S; Alzheimer Precision Medicine Initiative. Future avenues for Alzheimer’s disease detection and therapy: liquid biopsy, intracellular signaling modulation, systems pharmacology drug discovery. Neuropharmacology. 2021 Mar 1;185:108081. doi: 10.1016/j.neuropharm.2020.108081. Epub 2020 May 11. PMID: 32407924.
2 https://assets.researchsquare.com/files/rs-189177/v1/65385792-095a-4505-90c4-c0b85c76dbd1.pdf.
3 ClinicalTrials.gov Identifier: NCT03790709.
4 Hampel H. et al., 2018. Full genomic analysis of ANAVEX®2-73 phase 2a Alzheimer’s disease study identifies biomarkers enabling targeted therapy and a precision medicine approach. Alzheimer’s & Dementia 14, P1519–P1520. https://doi.org/10.1016/j.jalz.2018.07.027.
5 Hampel H. et al. (2020). A precision medicine framework using artificial intelligence for the identification and confirmation of genomic biomarkers of response to an Alzheimer’s disease therapy: Analysis of the blarcamesine (ANAVEX2‐73) Phase 2a clinical study. Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 6(1), e12013.
6 https://www.anavex.com/proof-of-concept-controlled-phase-2-clinical-trial-data-evaluating-anavex2-73-blarcamesine-in-parkinsons-disease-dementia-presented-at-ctad-2020-conference/.
7 Wesnes K. et al., Computerized cognition assessment during acetylcholinesterase inhibitor treatment in Alzheimer’s disease. Acta Neurol Scand 2010; 122:270–7.
8 Solomon T.M. et al., Correlational analysis of 5 commonly used measures of cognitive functioning and mental status: an update. Am J Alzheimers Dis Other Demen. 2014 Dec;29(8):718-22.
9 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020690s042,021720s014,022568s011lbl.pdf (2018).
10 Source: Biogen, EMERGE Phase III study, slide 24, https://investors.biogen.com/static-files/8e58afa4-ba37-4250-9a78-2ecfb63b1dcb (2020).
11 Thomas RG, Albert M, Petersen RC, Aisen PS. Longitudinal decline in mild-to-moderate Alzheimer’s disease: Analyses of placebo data from clinical trials. Alz & Dem 2016; 12: 598-603
12 Doody RS et al. (2013) N Engl J Med; 369:341-350
13 ClinicalTrials.gov Identifier: NCT03790709
14 Advances in Experimental Medicine and Biology Volume 964 (2017) Sigma Receptors: Their Role in Disease and as Therapeutic Targets.
15 https://www.nia.nih.gov/health/alzheimers; https://www.alz.org/alzheimers-dementia/facts-figures;
16 Alzheimer’s Disease International. World Alzheimer Report 2019. https://www.alz.co.uk/research/WorldAlzheimerReport2019.pdf.
17 AARP. 2020 Report: Caregiving in the U.S. https://www.aarp.org/content/dam/aarp/ppi/2020/05/full-report-caregiving-in-the-united-states.doi.10.26419-2Fppi.00103.001.pdf.
Artificial Intelligence
Kanazawa University research: Biochemical tails tell a story
KANAZAWA, Japan, April 24, 2024 /PRNewswire/ — Researchers at Nano Life Science Institute (WPI-NanoLSI), Kanazawa University report in Nano Letters how the use of high-speed atomic force microscopy helps to understand the crucial role played by certain biomolecules in DNA wrapping dynamics.
In plants and animals, the basic packaging units of DNA, which carry genetic information, are the so-called nucleosomes. A nucleosome consists of a segment of DNA wound around eight proteins known as histones. During gene expression (the process lying at the basis of protein production), nucleosomes are involved in various dynamical structural changes, such as nucleosome sliding, DNA unwrapping and other DNA–histone interactions. Of particular importance in these processes are the end structures, or tails, of the histones. Histone tails undergo chemical modifications, changing the histone’s functionality as needed. Detailed studies, and especially visualizations, of nucleosome dynamics are crucial for better understanding the role of histone tails. Mikihiro Shibata from Kanazawa University and colleagues have now succeeded in making video recordings of tail-less nucleosomes, showing that the absence of histone tails significantly increases a nucleosome’s dynamic activity.
The scientists used high-speed atomic force microscopy (HS-AFM), a powerful nanoimaging tool for visualizing molecular structures and their dynamics at high spatial and temporal resolution. For this, the nucleosomes needed to be put onto a substrate. Shibata and colleagues used a film of so-called pillar[5]arenes (molecules with a pentagonal tubular structure) as the substrate, forming an ideal surface as the nucleosomes are easily adsorbed to it without dynamical processes getting suppressed.
The researchers first looked at nucleosomes for which all eight histones lacked tails. Based on their HS-AFM observations, they concluded that nucleosome sliding and DNA unwrapping/rewrapping occurred more often than for normal (canonical) nucleosomes. This suggests that without tails, the histone–DNA interaction is weakened, leading to a situation in which DNA can more easily detach from the histones.
To better understand the roles of specific histone tails, Shibata and colleagues prepared nucleosomes where one type of histone was tailless. There are four different types of histones, called H2A, H2B, H3 and H4. HS-AFM experiments on the nucleosomes revealed that H2B and H3 tail-less nucleosomes showed an increased frequency of dynamics. Conversely, this means that canonical H2B and H3 histones are essential for nucleosome stability.
The scientists point out that they could not observe any actual motion of histone tails — most likely the temporal resolution of the study, 0.3 seconds, was much slower than the rate of the wrapping/unwrapping dynamics of the tails. Despite this limitation, the work of Shibata and colleagues clearly proves that the tails of H2B and H3 histones are the main contributors to nucleosome dynamics. Regarding future work, quoting the researchers, “a technique for tagging histone tail tips might enable HS-AFM to capture the movements of the histone tails themselves.”
Background
High-speed atomic force microscopy
The general principle of atomic force microscopy (AFM) is to make a very small tip scan the surface of a sample. During this horizontal (xy) scan, the tip, which is attached to a small cantilever, follows the sample’s vertical (z) profile, inducing a force on the cantilever that can be measured. The magnitude of the force at the xy position can be related to the z value; the xyz data generated during a scan then result in a height map providing structural information about the investigated sample. In high-speed-AFM (HS-AFM), the working principle is slightly more involved: the cantilever is made to oscillate near its resonance frequency. When the tip is moved around a surface, the variations in the amplitude (or the frequency) of the cantilever’s oscillation — resulting from the tip’s interaction with the sample’s surface — are recorded, as these provide a measure for the local z value. AFM does not involve lenses, so its resolution is not restricted by the so-called diffraction limit as in X-ray diffraction, for example.
HS-AFM results in a video, where the time interval between frames depends on the speed with which a single image can be generated (by xy-scanning the sample). Researchers at Nano Life Science Institute (WPI-NanoLSI), Kanazawa University have in recent years developed HS-AFM further, so that it can be applied to study biochemical molecules and biomolecular processes in real-time. Mikihiro Shibata and colleagues have now applied the method to study nucleosome dynamics in detail, and in particular the role of the molecular endings of histones — proteins that play a crucial role in DNA accessibility.
Reference
Shin Morioka, Takumi Oishi, Suguru Hatazawa, Takahiro Kakuta, Tomoki Ogoshi, Kenichi Umeda, Noriyuki Kodera, Hitoshi Kurumizaka, and Mikihiro Shibata. High-Speed Atomic Force Microscopy Reveals the Nucleosome Sliding and DNA Unwrapping/Wrapping Dynamics of Tail-less Nucleosomes, Nano Letters ,2024.
DOI: 10.1021/acs.nanolett.4c00801https://pubs.acs.org/doi/10.1021/acs.nanolett.4c00801
https://nanolsi.kanazawa-u.ac.jp/wp/wp-content/uploads/Figure-1-12.png Figure 1.
High-speed atomic force microscopy visualization of nucleosome dynamics with canonical (top) and tail-less (bottom) histones.© 2024 American Chemical Society
ContactHiroe YonedaSenior Specialist in Project Planning and OutreachNanoLSI Administration Office, Nano Life Science Institute (WPI-NanoLSI)Kanazawa UniversityKakuma-machi, Kanazawa 920-1192, JapanEmail: [email protected]: +81 (76) 234-4555
About Nano Life Science Institute (WPI-NanoLSI), Kanazawa University
Understanding nanoscale mechanisms of life phenomena by exploring “uncharted nano-realms”
Cells are the basic units of almost all life forms. We are developing nanoprobe technologies that allow direct imaging, analysis, and manipulation of the behavior and dynamics of important macromolecules in living organisms, such as proteins and nucleic acids, at the surface and interior of cells. We aim at acquiring a fundamental understanding of the various life phenomena at the nanoscale.https://nanolsi.kanazawa-u.ac.jp/en/
About the World Premier International Research Center Initiative (WPI)
The WPI program was launched in 2007 by Japan’s Ministry of Education, Culture, Sports, Science and Technology (MEXT) to foster globally visible research centers boasting the highest standards and outstanding research environments. Numbering more than a dozen and operating at institutions throughout the country, these centers are given a high degree of autonomy, allowing them to engage in innovative modes of management and research. The program is administered by the Japan Society for the Promotion of Science (JSPS).
See the latest research news from the centers at the WPI News Portal: https://www.eurekalert.org/newsportal/WPI
Main WPI program site: www.jsps.go.jp/english/e-toplevel
About Kanazawa University
As the leading comprehensive university on the Sea of Japan coast, Kanazawa University has contributed greatly to higher education and academic research in Japan since it was founded in 1949. The University has three colleges and 17 schools offering courses in subjects that include medicine, computer engineering, and humanities.
The University is located on the coast of the Sea of Japan in Kanazawa – a city rich in history and culture. The city of Kanazawa has a highly respected intellectual profile since the time of the fiefdom (1598-1867). Kanazawa University is divided into two main campuses: Kakuma and Takaramachi for its approximately 10,200 students including 600 from overseas.http://www.kanazawa-u.ac.jp/e/
View original content:https://www.prnewswire.co.uk/news-releases/kanazawa-university-research-biochemical-tails-tell-a-story-302125876.html
Artificial Intelligence
Geek+ and System Teknik deploy first PopPick solution in the Nordics for the pharmacy group Med24.dk
DUSSELDORF, Germany, April 24, 2024 /PRNewswire/ — Geekplus, the global leader in mobile robot and smart logistics solutions, has deployed the first Shelf-to-Person PopPick project in the Nordics for one of the biggest online pharmacy wholesalers in the region, Med24.dk. System Teknik partnered on the Denmark project, which includes three PopPick stations and 30 Shelf-to-Person robots, bringing a flexible solution to a region where fixed automation still dominates.
“With the rise of e-commerce, Med24.dk had been struggling with huge sales growth coupled with fast delivery demands from customers in Denmark, Norway, Sweden searching for pharmacy, health and beauty products. Peak season events had also caused considerable strain to their operations,” said Blond Shkodrani, channel partner manager for the Nordics at Geekplus. “Due to their overwhelming success, Med24.dk needed a modular, automated order fulfillment solution for fast, efficient order fulfillment.”
The Geekplus modular Shelf-to-Person solution optimizes warehouse operations using mobile robots to transport shelves. In a region where fixed and cubic solutions have been the trend during recent years, Shelf-to-Person handles goods of all sizes while removing the need for infrastructure investment, making it the most flexible response to order fulfillment challenges.
PopPick workstations use two retrieval arms and four presentation locations to present pickers with multiple, moveable 78-tote racks at one time, resulting in an industry-leading throughput of 450 totes per hour. PopPick can store goods of all types and sizes; the solution is not limited to small pieces and improves ergonomics for workers while picking. It also takes up less space than traditional systems, so customers can use more stations without adding facility space.
“We are very pleased to invest in flooring robots from Geekplus,” said Med24.dk CEO Nils Træholt. “We believe that this new and innovative technology can help us realize our growth ambitions, while maintaining good delivery times for the benefit of our customers.”
Morten Kirch, System Teknik’s CSO, added: “Due to Med24.dk’s growth, we are thrilled to be able to deliver a tailor-made, automated solution that matches their needs.”
Geekplus offers a suite of Goods-to-Person mobile order fulfillment solutions — the only comprehensive robotic offering controlled by a single software platform.
“Through trusted partners like System Teknik, we’re showing customers all over Europe that Geekplus truly is a one-stop shop for modular warehouse automation,” Shkodrani said.
Photo – https://mma.prnewswire.com/media/2395198/Med24_Geekplus_PopPick.jpg Logo – https://mma.prnewswire.com/media/2373458/Geekplus_logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/geek-and-system-teknik-deploy-first-poppick-solution-in-the-nordics-for-the-pharmacy-group-med24dk-302125816.html
Artificial Intelligence
VdoCipher’s Video Piracy Tracker Engine Blocks 60,000+ Pirates on 700+ Platforms
The company has global footprints across 120+ countries, serves over 10,000+ content creators, and educators across 3,000+ platforms
GURUGRAM, India, April 24, 2024 /PRNewswire/ — VdoCipher, a leading provider of video player and piracy protection solutions for content creators, e-learning, and media platforms, has announced significant success in combating video piracy with its latest innovation, the Piracy Tracker Engine. In just six months, this cutting-edge technology has blocked over 60,000 piracy attempts across 700+ content platforms, reinforcing VdoCipher’s commitment to safeguarding digital content and revenues.
For over eight years, VdoCipher has been pioneering DRM Encryption and Dynamic Watermark technologies, offering robust security solutions to content creators worldwide. Six months ago, the company introduced the Piracy Tracker and Hacker Identification Engine, aimed at identifying and blocking piracy attempts. This innovative solution targets various forms of piracy, including DRM breaches, credential sharing, and illegal clone applications.
VdoCipher, with a significant presence across the European market, serves over 10,000+ content creators across 3,000 platforms. Vibhav Sinha, CTO, VdoCipher, commented, “Every year we try to add an additional layer of technology to our security stack. Adding to strong Video DRM encryption, we now identify a combination of 12 viewer behavior patterns using our secure player. We provide an easy-to-use dashboard for our customers to get all piracy info. Some of the popular e-learning platforms have already made use of this tool to catch hackers, grow users, and enhance their revenues.”
The proliferation of internet video piracy tools poses a significant challenge, particularly in Europe. Recent statistics reveal that streaming accounted for 58% of piracy in the EU in 2022, with downloading comprising 32%. Top 10 popular global video downloaders have 110+ Million users.
Additionally, a report analyzing online piracy facts worldwide shows that Europeans have the biggest piracy problem (45.72%). In Italy, Spain, Portugal, Germany, UK and France, film piracy has soared during the Covid19 pandemic. Moreover, Telegram and other platforms have facilitated the widespread dissemination of pirated content, with hundreds of groups each having over 10,000 users leaking course videos.
In the past six months, VdoCipher’s Piracy Tracker Engine has yielded impressive results:
63,210 sessions blocked for potential piracy attempts.12,330 unique devices/IPs blocked.1,690 users were detected for credential misuse.384 user accounts proactively blocked based on piracy data.Legal actions were initiated against 5 users.Siddhant Jain, CEO of VdoCipher, emphasized, “One problem in online education and the content creator economy that no one talks about is video piracy. Video piracy robs creators of revenue but also robs students of learning from good-quality teachers. Teachers fear putting their best content online due to piracy; so ultimately, it also harms the student community. At VdoCipher, with our video hosting solutions, it is our mission to bring more educators and content creators online by ensuring that they do not lose revenues due to online piracy; at the same time, viewers across the globe have the best viewing experience.”
Contact: Siddhant [email protected]
Logo: https://mma.prnewswire.com/media/2394780/VdoCipher_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/vdociphers-video-piracy-tracker-engine-blocks-60-000-pirates-on-700-platforms-302124573.html
-
Artificial Intelligence7 days ago
Huawei Introduces AI Technologies to Accelerate Network Transformation Towards All Intelligence in the Net5.5G Era
-
Uncategorized5 days ago
Generative AI gold rush drives IT spending — with payoff in question
-
Uncategorized5 days ago
Do underwriters trust artificial intelligence?
-
Uncategorized5 days ago
Hans Jonas on Responsibility in the Age of Artificial Intelligence
-
Uncategorized5 days ago
Meta AI Assistant Adds Website, Expands Beyond US
-
Artificial Intelligence5 days ago
Free Your Hands, QIDI Vida Smart AR Glasses Lead the Way in New Sports Experience.
-
Uncategorized5 days ago
Can artificial intelligence reduce vehicle time to market?
-
Uncategorized5 days ago
The Ottawa Hospital doctors to try AI for patient notes